GYNO PEVARYL 150 mg Ov B/3

Vaginal ovule.
Box of 3 ovules, in thermoformed blister strip.

For one ovule :

Econazole nitrate: 150 mg

Local treatment of vulvovaginal mycoses, whether or not superinfected with Gram-positive bacteria.

Dosage

In the majority of cases:

For 3 consecutive days, 1 ovule at bedtime in the evening to be inserted deep into the vagina, preferably in the lying position.

In other cases:

In case of recurrence, and if the culture test is positive one week after treatment, a second course of treatment must be carried out.

Practical advice

Washing with a soap with neutral or alkaline pH.

Treatment will be accompanied by hygiene advice (wearing cotton underwear, avoiding vaginal douches, avoiding wearing periodic tampons during treatment...) and, as far as possible, removal of predisposing factors.

Do not interrupt treatment during menstruation.

Treatment of the partner will be discussed on a case-by-case basis.

To treat vulvar or perianal extensions of the mycosis, it is recommended to combine the gynecological ovules with a topical antifungal application.

Pregnant women must wash their hands thoroughly before administering GYNO-PEVARYL (see section Fertility, pregnancy and breastfeeding).

Special populations

Paediatric population

The safety and efficacy have not been demonstrated in children under 16 years.

Elderly patients

Data on the use of GYNO-PEVARYL in elderly people (> 65 years) are insufficient.

Hypersensitivity to the active substance, to other imidazole derivatives or to any of the excipients listed in section Composition.

In combination with latex condoms or diaphragms, due to the risk of rupture of latex diaphragms or condoms.

For vaginal use only. GYNO-PEVARYL is not intended for oral use.

Special warnings

In the absence of suggestive clinical symptoms, the mere finding of Candida on the skin or mucous membranes cannot in itself constitute an indication.

Once candidiasis is confirmed, the ecological factors that allow and promote the development of Candida must be carefully investigated.

To avoid relapses, eradication and management of predisposing factors is essential.

It is advisable to treat simultaneously any associated Candida focus recognized as pathogenic.

Patients using spermicidal contraceptives should consult their doctor because any local vaginal treatment may inactivate the spermicidal contraceptive (see section Interactions).

Patients with sensitivity to imidazoles have also shown sensitivity to econazole nitrate.

Precautions for use

In case of local intolerance, significant irritation or allergic reaction, treatment should be discontinued.

The use of a soap with an acidic pH (a pH that promotes the multiplication of Candida) is not recommended: see section Dosage and administration.

Contraindicated combinations

+ Latex male condoms/Latex diaphragms

Risk of rupture of the latex diaphragm or condom.

Combinations not recommended

+ Spermicides

Any local vaginal treatment may inactivate a local spermicidal contraception (see section Warnings and precautions).

Associations requiring precautions for use

+ Oral anticoagulants

Econazole is a known inhibitor of CYP3A4/2C9. Despite limited systemic passage after vaginal application, clinically significant interactions may occur and have been reported in patients taking oral anticoagulants such as warfarin and acenocoumarol (increased effect of the oral anticoagulant and bleeding risk).

In these patients, precautions should be taken and the INR should be monitored more frequently.

Adjustment of the oral anticoagulant dosage may prove necessary during treatment with econazole and after its discontinuation.

Pregnancy

Animal studies have not shown a teratogenic effect but have shown foetotoxicity at high doses (see section Preclinical safety). It is not known whether these results are relevant to humans.

In the absence of a teratogenic effect in animals, a malformative effect in humans is not expected. Indeed, to date, substances responsible for malformations in humans have proven teratogenic in animals in well-conducted studies in two species.

In clinical practice, no particular malformative or foetotoxic effect has appeared to date. However, monitoring of pregnancies exposed to econazole is insufficient to exclude any risk.

Due to absorption through the vaginal mucosa, the use of GYNO-PEVARYL should not be considered during the 1^er trimester of pregnancy unless the doctor considers it necessary.

GYNO-PEVARYL can be used during the 2^th and 3^th trimesters of pregnancy if the potential benefit to the mother outweighs the potential risk to the fetus.

Breast-feeding

Absorption of econazole nitrate through the vaginal mucosa is low.

It is not known whether econazole nitrate passes into human breast milk.

Breastfeeding is possible, but caution is required when GYNO-PEVARYL is used in a breastfeeding patient.

The tolerability of GYNO-PEVARYL was evaluated in 3630 patients who participated in 32 clinical trials. Based on the pooled tolerability data from these clinical trials, the most frequently reported adverse reactions (in % incidence) are skin and subcutaneous tissue disorders, such as pruritus (1,2 %) and skin burning sensation (1,2 %).

The table below presents the adverse reactions reported with vaginal use of GYNO-PEVARYL during the clinical trials (including the adverse reactions mentioned above) as well as adverse reactions from post-marketing data (spontaneous reports).

For adverse reactions reported during the clinical trials, the frequency categories presented in the table are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000).

For adverse reactions reported from spontaneous notification data, their frequency is not determinable (cannot be estimated from the available data).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr

In case of overdose with GYNO-PEVARYL, the expected adverse events are similar to the adverse reactions listed in section Adverse effects.

In case of accidental ingestion, nausea, vomiting or diarrhoea may occur. Symptomatic treatment should be carried out if necessary.

Pharmacotherapeutic class: ANTI-INFECTIVES AND ANTISEPTICS FOR GYNAECOLOGICAL USE, ATC code: G01AF05.

Econazole nitrate is an imidazole derivative with antifungal and antibacterial activity.

The activity has been demonstrated in vitro and acts on the agents responsible for cutaneous-mucosal mycoses:

• Candida and other yeasts (agents of vaginal mycoses),
• Gram-positive bacteria sometimes responsible for superinfection.

In vitro, attempts to select strains of Candida albicans resistant to econazole did not reveal acquired resistance; in vivo, this risk is negligible.

Mechanism of action

Different from that of antibiotics, it occurs at several levels: membrane (increased permeability), cytoplasmic (inhibition of oxidative processes at the level of the mitochondria), nuclear (inhibition of RNA synthesis).

This dosage is suitable for short-term treatment.

Absorption

In humans, econazole is poorly absorbed after vaginal administration.

The maximum concentrations of econazole and/or its metabolites in plasma or serum observed 1-2 days after administration are approximately 65 ng/mL for a 150 mg ovule. For a 150 mg ovule, approximately 5 % of the econazole dose is absorbed.

Distribution

In the systemic circulation, econazole and/or its metabolites are strongly bound (> 98 %) to plasma proteins.

Biotransformation and elimination

Econazole is extensively metabolised by oxidation, deamination and/or O-dealkylation, and the metabolites are eliminated via the renal and faecal routes.

The excipient forms a fine, adherent emulsion that allows penetration of econazole nitrate into all the folds of the vaginal mucosa.

Sub-chronic toxicity

The liver has been identified as the target organ. The safety margin associated with this effect is large.

Reproductive function

The studies carried out have not revealed any impairment of fertility, nor teratogenicity, but foetotoxicity at high doses.

Breast-feeding

Following oral administration of econazole nitrate to lactating rats, econazole and/or its metabolites were excreted into the milk and found in the suckling pups.

Genotoxicity

The studies carried out suggest the induction of aneuploidy, and some studies indicate a mutagenic effect. Taken together, however, these studies indicate that the genotoxic effects are limited.

Local tolerance

The studies performed revealed no cutaneous or vaginal irritation, no phototoxicity and no sensitisation.

3 years.

To be stored at a temperature not exceeding +30 °C.

No special requirements.